Biogen Inc. (BMV:BIIB)

Market Cap	398.53B
Revenue (ttm)	188.53B
Net Income (ttm)	28.86B
Shares Out	n/a
EPS (ttm)	197.14
PE Ratio	13.81
Forward PE	9.58
Dividend	n/a
Ex-Dividend Date	n/a

Volume	38
Average Volume	294
Open	2,950.00
Previous Close	2,850.02
Day's Range	2,950.00 - 2,950.00
52-Week Range	2,395.00 - 3,801.00
Beta	0.13
RSI	55.74
Earnings Date	Oct 30, 2025

About Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1978
• Employees: 7,605
• Stock Exchange: Mexican Stock Exchange
• Ticker Symbol: BIIB

Financial Performance

In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.

Financial numbers in USD